Delivery Order SPE2DB22D2006-SPE2DB25FW2RJ
- Not listed
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for Lupron Depot 11.25 mg 3-month kits, valued at $4,474.82 with a firm fixed price structure. This competitively awarded delivery order, with no set-aside designation, is scheduled for completion by August 18, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Lupron Depot 11.25 mg 3-month kits, valued at $33,612.02. This firm fixed-price delivery order, with an ultimate completion date of August 12, 2025, represents a competitively awarded, non-set-aside procurement with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,331.98 to AmerisourceBergen Drug Corp for Lupron Depot 45 mg 6-month kits under a firm fixed price contract. The award was issued on July 24, 2025, with an ultimate completion date of July 25, 2025. This delivery order represents a non-set-aside award issued competitively to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company is headquartered. Lupron Depot is a hormone therapy...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $6,167.84 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Lupron Depot 22.5 mg 3-month kits. This is a firm fixed price delivery order with no set-aside designation, and performance is scheduled for completion by July 29, 2025, at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Lupron Depot 11.25 mg 3-month kits with a ceiling value of $11,281.85. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The product will be delivered to the company's corporate...
- The Defense Logistics Agency Medical Supply Chain awarded a $42,779.28 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Lupron Depot 11.25 mg 3-month kits, with final delivery required by July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for Lupron Depot 11.25 mg 3-month kits valued at $7,855.98 under a firm fixed-price contract. This non-set-aside delivery order is scheduled for completion by August 11, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement through the company's existing...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Lupron Depot 3.75 mg kits, valued at $15,025.58 under a firm fixed-price contract type. The order, which has an ultimate completion date of July 29, 2025, represents a non-set-aside award and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,665.78 to AmerisourceBergen Drug Corp for Lupron Depot 22.5 mg 3-month kits, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of pharmaceutical supply services to support federal military and healthcare operations. The contract involves no set-aside designation and will be performed at the vendor's corporate office location in...
- The Defense Logistics Agency awarded a $28,548.57 delivery order to AmerisourceBergen Drug Corp for Lupron Depot 11.25 mg 3-month treatment kits on August 4, 2025, with a completion date of August 5, 2025. This firm fixed-price contract was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Lupron Depot is a hormone therapy medication commonly used in military and federal healthcare systems for...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW2RJDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Lupron Depot 22.5 mg 3-month kits, with a ceiling value of $1,941.48 and a firm fixed price structure. This delivery order represents no set-aside designation and is set to be completed by July 22, 2025. AmerisourceBergen Drug Corp will perform the work at its corporate office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and healthcare solutions provider, the company serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through competitively awarded contracts. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and runs through December 2026. That prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The current delivery order for Lupron Depot, a hormone therapy medication used in treating conditions such as prostate cancer and endometriosis, reflects the company's ongoing role in supplying specialized medications to the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 7/21/25 |